Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Focus On Clinical Trial Review Process In China Before Timeline Reform – Merck Exec

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON - Companies pushing to shorten the clinical trial approval timeline in China should instead focus first on promoting education to improve the review process, according to Merck Clinical Research Operations-Asia Pacific Director Zili Li, who also heads the company's China regulatory policy

You may also be interested in...



Global Trials In China Rich But Challenging – Wyeth Exec

TOKYO - Clinical trials in China have much potential and can be rewarding if pharmaceutical companies are willing to overcome challenges such as working with young researchers in China, who may not have much pharmaceutical experience, said Ling Su, Wyeth vice president of clinical research and development for Asia Pacific

Global Trials In China Rich But Challenging – Wyeth Exec

TOKYO - Clinical trials in China have much potential and can be rewarding if pharmaceutical companies are willing to overcome challenges such as working with young researchers in China, who may not have much pharmaceutical experience, said Ling Su, Wyeth vice president of clinical research and development for Asia Pacific

Industry Should Encourage Clinical Trial Reform In China – Shanghai R&D Panel

SHANGHAI - The pharmaceutical industry should take advantage of China's desire to become a destination of choice for global clinical trials to encourage streamlining of regulatory requirements and expansion of clinical study sites, according to an April 1 panel discussion during the China 2008 Pharmaceutical R&D Summit in Shanghai

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel